OA4-3 PD-1 blockade combined with ART improves SIV-specific CD8 T cell function and enhances control of pathogenic SIV after ART interruption

• G.H. Mylvaganam,
• S. Hicks,
• B. Lawson,
• M. Nega,
• V. Velu,
• R. Ahmed,
• G.J. Freeman,
• R.R. Amara

Affiliations

G.H. Mylvaganam

Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta GA, 30329, USA

S. Hicks

Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta GA, 30329, USA

B. Lawson

Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta GA, 30329, USA

M. Nega

Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta GA, 30329, USA

V. Velu

Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta GA, 30329, USA

R. Ahmed

Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta GA, 30329, USA

G.J. Freeman

Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA

R.R. Amara

Emory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta GA, 30329, USA